Biotech
News Alert: GenSpera (OTCQB:GNSZ) Presents Mipsagargin (G-202) HCC Clinical
Trial Update at 8th International Liver Cancer Association Conference
50% of
Patients Treated with Mipsagargin had No Tumor Growth at Four Months
SAN ANTONIO - September 8, 2014 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for
the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver
cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th
International Liver Cancer Association (ILCA) Conference on Saturday, September
6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD, will discuss these results in
further detail during the Company's presentation at the Rodman & Renshaw
16th Annual Global Investment Conference on Tuesday, September 9th at 12:05
p.m. Eastern.
GenSpera
presented a poster containing interim results from the Phase Ib and ongoing
Phase II study in HCC patients who had previously progressed on, or who were
intolerant of, sorafenib, a drug co-developed and co-marketed by Bayer and Onyx
Pharmaceuticals. Historically, this patient population has a median time to
progression of only two months when they enter subsequent clinical trials.
Impressively, 50% of patients exhibited stable disease (no tumor growth) at 4
months on study.
"Mipsagargin is differentiated from
most other drugs being tested in HCC due to its well-tolerated safety profile
and the significant proportion of patients that experience prolonged disease
stabilization while on treatment," stated Dr. Craig Dionne, GenSpera CEO.
"Liver cancer is the third largest cancer killer worldwide and is expected
to represent a $1.5 billion market by 2019. We are encouraged by these early
stage positive results and what they imply for our ongoing and planned Phase II
clinical trials for mipsagargin in glioblastoma, prostate cancer and renal cell
carcinoma patients."
Rodman & Renshaw 16th Annual Global
Investment Conference Details:
When: Tuesday, September 9th at 12:05 p.m.
Eastern
Where: The New York Palace Hotel in New
York City
To arrange a one-on-one meeting with
management, please contact Steve Gersten at steve@capmarketsgroup.com.
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/09081.asp
About GenSpera
GenSpera's technology platform combines a
powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system
that provides for the targeted release of drug candidates within a tumor.
Unlike typical chemotherapeutic agents, thapsigargin results in cell death
irrespective of the rate of cell division, which may provide an effective
approach to kill both fast- and slow-growing cancers. GenSpera's lead drug
candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high
levels in the vasculature of liver and glioblastoma cancers and in the
vasculature of almost all other solid tumors. Mipsagargin is therefore expected
to have potential efficacy in a wide variety of tumor types.
Mipsagargin Phase II clinical trials are
underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the
company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
About ILCA 2014
The 8th Annual International Liver Cancer
Association Conference was held September 5-7, 2014, at the Hotel Granvia Kyoto
in Kyoto, Japan. The International Liver Cancer Association (ILCA) is an
international organization devoted exclusively to liver cancer research for
experts from all related disciplines. Visit the ILCA website at http://www.ilca2014.org.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking
statements. Investors are cautioned that statements in this press release
regarding potential applications of GenSpera's technologies constitute
forward-looking statements that involve risks and uncertainties, including,
without limitation, risks inherent in the development and commercialization of
potential products, uncertainty of clinical trial results or regulatory
approvals or clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements.
Additional information on potential factors that could affect our results and
other risks and uncertainties will be detailed from time to time in GenSpera's
periodic reports filed with the Securities and Exchange Commission.
CONTACT:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc. (210) 479-8112
Investors:
Steve
Gersten
Capital
Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920
Media:
Dawn
Van Zant
(800)
665 0411
Disclaimer/Disclosure: Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure:
Genspera (GNSZ) has engaged Investor Ideas for PR and news publication
effective June 18, 2014 (compensation of five thousand per month and average of
eleven thousand five hundred 144 shares per month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment